Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

UroGen Pharma (URGN) EBT (2016 - 2025)

Historic EBT for UroGen Pharma (URGN) over the last 10 years, with Q3 2025 value amounting to -$34.4 million.

  • UroGen Pharma's EBT fell 4587.82% to -$34.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$161.6 million, marking a year-over-year decrease of 4517.56%. This contributed to the annual value of -$124.0 million for FY2024, which is 2615.64% down from last year.
  • Latest data reveals that UroGen Pharma reported EBT of -$34.4 million as of Q3 2025, which was down 4587.82% from -$48.9 million recorded in Q2 2025.
  • In the past 5 years, UroGen Pharma's EBT registered a high of -$21.9 million during Q3 2023, and its lowest value of -$48.9 million during Q2 2025.
  • For the 5-year period, UroGen Pharma's EBT averaged around -$29.8 million, with its median value being -$28.1 million (2022).
  • As far as peak fluctuations go, UroGen Pharma's EBT surged by 2135.56% in 2023, and later tumbled by 5730.98% in 2024.
  • Quarter analysis of 5 years shows UroGen Pharma's EBT stood at -$27.3 million in 2021, then dropped by 3.17% to -$28.2 million in 2022, then rose by 21.36% to -$22.2 million in 2023, then tumbled by 57.31% to -$34.9 million in 2024, then grew by 1.33% to -$34.4 million in 2025.
  • Its EBT stands at -$34.4 million for Q3 2025, versus -$48.9 million for Q2 2025 and -$43.5 million for Q1 2025.